Department of Pediatrics, Faculty of Medicine, Kuwait.
Communicable Diseases Control Unit, Department of Public Health, Ministry of Health, Kuwait.
J Infect Public Health. 2015 Sep-Oct;8(5):441-7. doi: 10.1016/j.jiph.2015.01.009. Epub 2015 Mar 14.
The introduction of Haemophilus influenzae type b (Hib) conjugate vaccine and conjugate pneumococcal vaccine into routine childhood vaccination in Kuwait has resulted in the emergence of Neisseria meningitidis as the leading cause of invasive bacterial infection in children. Currently, a quadrivalent ACYW-135 meningococcal polysaccharide vaccine is administered as part of routine childhood vaccination in Kuwait at the age of 2 years. Conjugate meningococcal vaccines have been shown to be more effective in preventing meningococcal infection in young children. The objective of this study was to describe the epidemiology of meningococcal disease (MD) in Kuwait and evaluate the need for conjugate vaccine in routine childhood immunization. We have reviewed the MD surveillance data from the communicable disease unit, Ministry of Health, Kuwait during the period from 1987 to 2013. The analysis included microbiologically confirmed cases of N. meningitidis in the blood and cerebrospinal fluid. There were 293 cases of confirmed MD during the study period. Two hundred and four cases (70%) were in children ≤ 14 years of age. The mean incidence rate was 0.5/100,000 persons. The dominant serogroups were W-135 and B, accounting for 80 cases (32%) each. Serogroup B accounted for 69/204 (34%) of all cases in children ≤ 14 years and serogroup A accounted for 36/89 40% of all adult cases. There were three outbreaks: 1987 (caused by serogroup A), 1989 (caused by serogroup W-135) and 2002 (caused by serogroup B). The mean case fatality rate was 13.5%. In conclusion, despite childhood routine vaccination with ACYW-135 polysaccharide vaccine, infants and young children remain at high risk for MD, which supports the introduction of conjugate meningococcal vaccine to the routine childhood vaccination schedule.
在科威特,将乙型流感嗜血杆菌(Hib)结合疫苗和结合型肺炎球菌疫苗引入常规儿童疫苗接种后,脑膜炎奈瑟菌已成为导致儿童侵袭性细菌感染的主要原因。目前,在科威特,四价 ACYW-135 脑膜炎球菌多糖疫苗作为常规儿童疫苗接种的一部分,在 2 岁时接种。结合型脑膜炎球菌疫苗已被证明在预防幼儿脑膜炎感染方面更为有效。本研究的目的是描述科威特脑膜炎奈瑟菌病(MD)的流行病学,并评估在常规儿童免疫接种中使用结合疫苗的必要性。我们审查了 1987 年至 2013 年期间,卫生部传染病股的 MD 监测数据。分析包括血液和脑脊液中分离的脑膜炎奈瑟菌微生物学确诊病例。研究期间有 293 例确诊 MD 病例。204 例(70%)为≤14 岁儿童。平均发病率为 0.5/100,000 人。主要血清群为 W-135 和 B,各占 80 例(32%)。血清群 B 占所有≤14 岁儿童病例的 69/204(34%),血清群 A 占所有成人病例的 36/89(40%)。发生了 3 次暴发:1987 年(由血清群 A 引起)、1989 年(由血清群 W-135 引起)和 2002 年(由血清群 B 引起)。平均病死率为 13.5%。总之,尽管儿童常规接种 ACYW-135 多糖疫苗,但婴儿和幼儿仍面临 MD 的高风险,这支持将结合型脑膜炎球菌疫苗引入常规儿童疫苗接种计划。